| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Belatacept |
| Brand | Nulojix® |
| Indication | In combination with corticosteroids and a mycophenolic acid (MPA), for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen. |
| Assessment Process | |
| Rapid review commissioned | 15/11/2011 |
| Rapid review completed | 23/01/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |